| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/20/2001 | CA2402908A1 Assay for agents that induce chemokinesis |
| 09/20/2001 | CA2402846A1 Treatment of rosacea |
| 09/20/2001 | CA2402772A1 Apolipoprotein-a-i regulation of t-cell signalling |
| 09/20/2001 | CA2402729A1 Human immune response proteins |
| 09/20/2001 | CA2402710A1 Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease |
| 09/20/2001 | CA2402413A1 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | CA2402402A1 Use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treating adverse effects of anti-parkinsonian drugs |
| 09/20/2001 | CA2402327A1 Peptides targeting specifically tumor-derived endothelial cells |
| 09/20/2001 | CA2402276A1 Carbohydrate system and a method for providing nutriton to a diabetic |
| 09/20/2001 | CA2401448A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | CA2401273A1 Il-17 receptor like molecules and uses thereof |
| 09/20/2001 | CA2400825A1 Three-dimensional model of a fc region of an ige antibody and uses thereof |
| 09/20/2001 | CA2373237A1 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 09/19/2001 | EP1134290A2 Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| 09/19/2001 | EP1134286A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/19/2001 | EP1133996A1 Medicinal compositions for periodic administration |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133989A2 Polymer compositions for use in therapy |
| 09/19/2001 | EP1133988A1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/19/2001 | EP1133987A1 Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
| 09/19/2001 | EP1133699A1 Prevention and treatment of amyloid-associated disorders |
| 09/19/2001 | EP1133692A1 Methods of identifying viral therapeutics |
| 09/19/2001 | EP1133575A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 09/19/2001 | EP1133557A2 Growth factor modulators |
| 09/19/2001 | EP1133552A2 Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| 09/19/2001 | EP1133516A1 Chromosome 17p-linked prostate cancer susceptibility gene |
| 09/19/2001 | EP1133500A1 Organophosphorous compounds and the use thereof |
| 09/19/2001 | EP1133318A1 Supramolecular complexes containing therapeutic agents |
| 09/19/2001 | EP1133315A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases |
| 09/19/2001 | EP1133311A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 09/19/2001 | EP1133310A2 Artery- and vein-specific proteins and uses therefor |
| 09/19/2001 | EP1133308A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
| 09/19/2001 | EP1133307A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
| 09/19/2001 | EP1133301A1 Anti-asthmatic combinations comprising surface active phospholipids |
| 09/19/2001 | EP1133299A1 2-hydroxymethylolanzapine compositions and methods |
| 09/19/2001 | EP1133294A1 Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases |
| 09/19/2001 | EP1133292A1 A new pharmaceutical composition |
| 09/19/2001 | EP1133290A1 Use of effectors of the central cholinergic nervous system |
| 09/19/2001 | EP1133285A1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 09/19/2001 | EP1133284A1 New process |
| 09/19/2001 | EP1133278A2 Delivery of liposomal-encapsulated antioxidants and applications thereof |
| 09/19/2001 | EP1133230A1 Dosage formulations for acetylcholinesterase inhibitors |
| 09/19/2001 | EP0918536B1 Composition comprising insulin and insulin-like growth factor-i (igf-i) |
| 09/19/2001 | CN1313903A Compound and method for the prevention and/or the treatment of allergy |
| 09/19/2001 | CN1313765A Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents |
| 09/19/2001 | CN1313756A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1071118C Pyrazolopyrimidone for treating impotence |
| 09/18/2001 | US6291643 Apaf-1 an activator of caspase-3 |
| 09/18/2001 | US6291642 Mammalian cell cycle protein |
| 09/18/2001 | US6291533 Dietary supplements for each specific blood type |
| 09/18/2001 | US6291516 Contacting the cell with a composition including at least one cyclic amp agonist. |
| 09/18/2001 | US6291509 Synergistic immunosuppressant composition containing a 2,2'-bi-1H-pyrrole compound |
| 09/18/2001 | US6291500 Administering an antifungal agent |
| 09/18/2001 | US6291495 Insulin sensitizer; and a sulfonylurea, a biguanide, or an alpha-glucosidase inhibitor. |
| 09/18/2001 | US6291486 Polycyclic Dihydrothiazoles, their preparation and use as pharmaceuticals |
| 09/18/2001 | US6291480 Diaryl piperidyl pyrrole derivatives as antiprotozoal agents |
| 09/18/2001 | US6291468 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss |
| 09/18/2001 | US6291466 Cholinergic agents in the treatment of presbyopia |
| 09/18/2001 | US6291446 Particularly using the isozyme selective pkc inhibitor, (s)-3,4-(n,n'-1,1'-((2?-ethoxy)-3'?(o)-4'?-(n, n-dimethylamino)-butane)-bis-(3,3'-indolyl))-1(h)-pyrrole-2,5-dione hydrochloride salt. |
| 09/18/2001 | US6291437 The protein/nucleic acid compositions are administered in an amount capable of inducing cell mediated immunity and/or antibody response in the subject. |
| 09/18/2001 | US6291430 Mage-3 peptides presented by HLA class II molecules |
| 09/18/2001 | US6291217 Glutathionylspermidine synthetase and processes for recovery and use thereof |
| 09/18/2001 | US6291195 Generating ligands which bind preferential human receptors; incubate cells expressing preferential binding protein with modulator, detect adjustment in binding activity |
| 09/18/2001 | US6291175 Methods for treating a neurological disease by determining BCHE genotype |
| 09/18/2001 | US6290987 Alkali metal alkyl sulfate, at least one membrane mimetic amphiphile, and at least one phospholipid. |
| 09/18/2001 | US6290952 Method of dephosphorylating an endotoxin in vivo with alkaline phosphatase |
| 09/18/2001 | US6290951 Alteration of the cell cycle in vivo, and particularly for inducing apoptosis of tumor cells |
| 09/18/2001 | US6290929 Cancer treatment |
| 09/18/2001 | US6290712 Laser/sensitizer assisted immunotherapy |
| 09/18/2001 | US6289892 Partial liquid breathing of fluorocarbons |
| 09/18/2001 | CA2238879C Thereapeutic applications for the anti-t-bam (cd40-l) monoclonal antibody 5c8 |
| 09/18/2001 | CA2145182C Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| 09/13/2001 | WO2001067110A1 Synergistic activation of regulatory elements by rel proteins and a steroid receptor |
| 09/13/2001 | WO2001067107A1 Modulation of histone deacetylase |
| 09/13/2001 | WO2001066785A1 Phosphatidyl serine receptors and uses thereof |
| 09/13/2001 | WO2001066772A2 Heparinase iii and uses thereof |
| 09/13/2001 | WO2001066753A2 Human genes and gene expression products |
| 09/13/2001 | WO2001066742A2 G-protein coupled receptors |
| 09/13/2001 | WO2001066741A2 Kcnb: a novel potassium channel protein |
| 09/13/2001 | WO2001066716A1 Polypeptide having phosphodiesterase activity |
| 09/13/2001 | WO2001066601A1 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 09/13/2001 | WO2001066599A1 Crystal |
| 09/13/2001 | WO2001066595A2 Human fgf-23 gene and gene expression products |
| 09/13/2001 | WO2001066594A2 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | WO2001066548A1 New aza-indolyl derivatives |
| 09/13/2001 | WO2001066533A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | WO2001066151A1 Methods and kits for locally administering an active agent to an interstitial space of a host |
| 09/13/2001 | WO2001066147A2 Antimicrobial compounds and formulations |
| 09/13/2001 | WO2001066146A1 Methods and compositions for dietary supplements |
| 09/13/2001 | WO2001066145A1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails |
| 09/13/2001 | WO2001066144A2 Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066139A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 09/13/2001 | WO2001066135A1 Lowering serum lipids |
| 09/13/2001 | WO2001066125A1 DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4) |
| 09/13/2001 | WO2001066124A2 Composition for the treatment of heart failure |
| 09/13/2001 | WO2001066123A2 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | WO2001066117A1 Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
| 09/13/2001 | WO2001066113A1 Metabotropic glutamate receptor antagonists for treating tolerance and dependency |
| 09/13/2001 | WO2001066111A1 Compositions containing potential spla2 inhibitors for the treatment of pain |